Omeros Corporation (OMER)
Largest Insider Buys in Sector
OMER Stock Price History Chart
OMER Stock Performance
About Omeros Corporation
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for …
Insider Activity of Omeros Corporation
Over the last 12 months, insiders at Omeros Corporation have bought $40,500 and sold $0 worth of Omeros Corporation stock.
On average, over the past 5 years, insiders at Omeros Corporation have bought $40,500 and sold $1.56M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Demopulos Gregory A MD (Chairman, CEO & President) — $25,200. Demopulos Peter A MD (director) — $15,300.
The last purchase of 15,000 shares for transaction amount of $25,200 was made by Demopulos Gregory A MD (Chairman, CEO & President) on 2023‑11‑17.
List of Insider Buy and Sell Transactions, Omeros Corporation
| 2023-11-17 | Chairman, CEO & President | 15,000 0.0245% | $1.68 | $25,200 | +130.67% | |||
| 2023-11-15 | director | 10,000 0.0161% | $1.53 | $15,300 | +146.23% | |||
| 2023-05-22 | Sale | director | 5,000 0.0081% | $6.53 | $32,650 | -45.85% | ||
| 2023-05-22 | Sale | director | 5,000 0.008% | $6.46 | $32,300 | -45.85% | ||
| 2021-06-17 | Sale | CHAIRMAN, CEO & PRESIDENT | 36,857 0.0588% | $14.90 | $549,169 | -53.84% | ||
| 2021-06-15 | Sale | CHAIRMAN, CEO & PRESIDENT | 36,856 0.0596% | $15.02 | $553,577 | -53.29% | ||
| 2021-05-20 | Sale | CHAIRMAN, CEO & PRESIDENT | 36,856 0.0584% | $14.96 | $551,366 | -51.92% | ||
| 2021-05-19 | Sale | CHAIRMAN, CEO & PRESIDENT | 36,857 0.0594% | $17.07 | $629,149 | -57.10% | ||
| 2021-04-08 | Sale | CHAIRMAN, CEO & PRESIDENT | 35,206 0.0566% | $17.76 | $625,259 | -53.90% | ||
| 2021-04-07 | Sale | CHAIRMAN, CEO & PRESIDENT | 37,407 0.0599% | $17.91 | $669,959 | -54.24% | ||
| 2021-02-22 | Sale | VP FINANCE AND CAO | 8,100 0.0134% | $23.28 | $188,568 | -34.89% | ||
| 2021-02-19 | Sale | VP FINANCE AND CAO | 10,000 0.0155% | $22.64 | $226,400 | -37.23% | ||
| 2021-02-10 | Sale | VP FINANCE AND CAO | 1,900 0.0031% | $22.49 | $42,731 | -32.76% | ||
| 2021-01-19 | Sale | VP FINANCE AND CAO | 9,500 0.0157% | $19.95 | $189,525 | -21.58% | ||
| 2021-01-13 | Sale | director | 5,000 0.008% | $16.97 | $84,850 | -10.19% | ||
| 2020-05-13 | Sale | director | 5,000 0.0093% | $14.40 | $71,999 | +4.28% | ||
| 2019-12-03 | Sale | director | 20,000 0.0309% | $10.99 | $219,748 | -6.68% | ||
| 2019-10-14 | Sale | director | 10,000 0.0205% | $15.12 | $151,180 | -7.99% | ||
| 2018-08-31 | Sale | VP Patent and General Counsel | 15,058 0.0308% | $25.75 | $387,691 | -39.01% | ||
| 2018-08-30 | Sale | VP Patent and General Counsel | 70,000 0.0825% | $14.28 | $999,250 | -36.44% |
Insider Historical Profitability
| Demopulos Peter A MD | director | 208516 0.3598% | $4.52 | 7 | 0 | <0.0001% |
| Demopulos Gregory A MD | Chairman, CEO & President | 123945 0.2139% | $4.52 | 1 | 12 | |
| Aspiri Ray | director | 186872 0.3225% | $4.52 | 1 | 0 | <0.0001% |
| HANISH ARNOLD C | director | 0 0% | $4.52 | 1 | 1 | +0.81% |
Institutional Investor Ownership
| Ingalls Snyder Llc | $16.21M | 8.11 | 4.7M | +3.33% | +$522,267.54 | 0.76 | |
| BlackRock | $14.53M | 7.27 | 4.21M | -1.61% | -$237,063.30 | <0.0001 | |
| The Vanguard Group | $11.21M | 5.61 | 3.25M | +2.57% | +$280,650.60 | <0.0001 | |
| Stifel | $6.59M | 3.3 | 1.91M | +0.98% | +$63,669.86 | 0.01 | |
| D. E. Shaw & Co. | $5.79M | 2.9 | 1.68M | +12.42% | +$639,560.96 | 0.01 |